Want to see HYPD full AI Analyst Report?
HYPD Stock Chart & Stats
$3.85
--
Market closed
$3.85
--
Day’s Range― - ―
52-Week Range$2.49 - $15.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.09M
Market Cap
$41.84M
Enterprise Value$45.46
Total Cash (Recent Filing)$7.38M
Total Debt (Recent Filing)$9.07M
Price to Earnings (P/E)―
Beta3.14
Next Earnings
Aug 12, 2026EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.46
Shares Outstanding15,157,747
10 Day Avg. Volume701,310
30 Day Avg. Volume1,085,571
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.43
Price to Sales (P/S)21.88
P/FCF Ratio-1.21
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.30Price Target Upside89.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.8
Revenue Forecast (FY)$7.14M
Bulls Say, Bears Say
Bulls Say
Collaboration OpportunitiesCollaborations in dry eye disease development are seen as upside, with the user-filled Optejet potentially defining the most realistic shot for near-term progress.
Merger And DevelopmentThe proposed merger of topical ophthalmic platforms could present the next constructive chapter for Optejet and broader development.
Technological AdvancementThe new user-filled Optejet incorporates a sterile disposable cartridge that can be user-filled from a traditional eyedropper bottle, allowing consistent and precise spray delivery.
Bears Say
Clinical Trial ChallengesThe Phase 3 CHAPERONE trial failure for MicroPine has informed the assumptions for the price target.
Discontinued TrialsThe Phase 3 CHAPERONE trial using the Optejet optimized spray dispenser for delivering MicroPine atropine for reduction of pediatric progressive myopia was discontinued.
Market And Revenue RisksRisks to the investment thesis include failure of products and/or candidates to achieve peak commercial revenue estimates due to market size, penetration rates, and/or pricing.
Hyperion DeFi News
HYPD FAQ
What was Hyperion DeFi’s price range in the past 12 months?
Hyperion DeFi lowest stock price was $2.49 and its highest was $15.00 in the past 12 months.
What is Hyperion DeFi’s market cap?
Hyperion DeFi’s market cap is $41.84M.
When is Hyperion DeFi’s upcoming earnings report date?
Hyperion DeFi’s upcoming earnings report date is Aug 12, 2026 which is in 19 days.
How were Hyperion DeFi’s earnings last quarter?
Hyperion DeFi released its earnings results on May 14, 2026. The company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $1.32 by -$1.06.
Is Hyperion DeFi overvalued?
According to Wall Street analysts Hyperion DeFi’s price is currently Undervalued.
Does Hyperion DeFi pay dividends?
Hyperion DeFi does not currently pay dividends.
What is Hyperion DeFi’s EPS estimate?
Hyperion DeFi’s EPS estimate is 0.35.
How many shares outstanding does Hyperion DeFi have?
Hyperion DeFi has 15,157,747 shares outstanding.
What happened to Hyperion DeFi’s price movement after its last earnings report?
Hyperion DeFi reported an EPS of $0.26 in its last earnings report, missing expectations of $1.32. Following the earnings report the stock price went up 3.429%.
Which hedge fund is a major shareholder of Hyperion DeFi?
Currently, no hedge funds are holding shares in HYPD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hyperion DeFi Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.30 (89.61% Upside)
$7.30 (89.61% Upside)
Insider Transactions
Bought Shares
Worth $29.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-82.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1070.90%
Trailing 12-Months
Company Description
Hyperion DeFi
Operating from the United States, Hyperion DeFi, Inc. is a company undergoing a significant shift from its foundational work in ophthalmic drug-delivery, known as Optejet. Its current trajectory involves establishing itself as the inaugural U.S. firm on Nasdaq to hold a cryptocurrency treasury, predominantly denominated in HYPE tokens originating from the Hyperliquid blockchain. Furthermore, Hyperion DeFi oversees the "Kinetiq × Hyperion" validator, persists with its decentralized finance (DeFi) staking strategies, and continues to advance its Optejet UFD™ technology for ocular health.
HYPD Stock 12 Month Forecast
Average Price Target
$7.30
▲(89.61% Upside)
Technical Analysis
Cytosorbents
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Baird Medical Investment Holdings
―
Ownership Overview
15.51% Insiders
2.48% Mutual Funds
0.42% Other Institutional Investors
78.29% Public Companies and
Individual Investors